Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril

American Heart Journal

Volumn 123, Issue 5, 1992, Pages 1433-1438

  Kjeldsen, Sverre E ^a,b   Gupta, Rakesh K ^a,b   Krause, Lisa ^a,b   Weder, Alan B ^a,b   Julius, Stevo ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; QUINAPRIL;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT; DOUBLE-BLIND METHOD; HEMODYNAMICS; HUMAN; HYPERTENSION; ISOQUINOLINES; KIDNEY; MALE; MIDDLE AGE; REGIONAL BLOOD FLOW;

EID: 0026514687     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/0002-8703(92)91066-A     Document Type: Article

References (57)

1. Central haemodynamic effects of beta-blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol, pindolol, and bumitrolol
2. Physical performance and muscle metabolism during beta-adrenergic blockade in man
3. The effects of naloxone and timolol on plasma catecholamine levels during short-term dynamic exercise
4. Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise
5. Hemodynamic changes at rest and during exercise in long-term prazosin therapy for essential hypertension
6. Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise
7. Hemodynamic long-term effects of verapamil in essential hypertension at rest and during exercise
8. Haemodynamic effects of nifedipine in essential hypertension at rest and during exercise
9. Hemodynamic and volume changes associated with captopril
10. Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients
11. Long-term hemodynamic effects of enalapril at rest and during exercise in essential hypertension
12. An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients
13. A specific orally active inhibitor of angiotensin converting enzyme in man
14. The effects of angiotensin I-converting enzyme inhibitors on arterial blood pressure and urinary sodium excretion. Role of the renal renin-angiotensin and kallikrein-kinin systems
15. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension
16. Quinapril
17. Quinapril
18. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure
19. Quinapril: a double-blind, placebo-controlled trial in essential hypertension
20. The treatment of mild to moderate hypertension with ACE inhibitors
21. The safety and tolerability of quinapril
22. Hemodynamic effects of quinapril a novel angiotensin-converting enzyme inhibitor
23. Research utility of non-invasive methods for measurement of cardiac output
24. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study
25. Renal and endocrine response to saline infusion in essential hypertension
26. Measurement of renal clearance of insulin and PAH in the steady state without urine collection
27. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine
28. Angiotensin-converting enzyme inhibition, catecholamines and hemodynamics in essential hypertension
29. The role of renal hemodynamics in the antihypertensive effect of captopril
30. Effect of enalapril on ambulatory blood pressure, renal hemodynamics and cardiac function in essential hypertension
31. General and regional hemodynamic pattern underlying essential hypertension
32. Haemodynamics in early essential hypertension
33. Central hemodynamics in essential hypertension at rest and during exercise: a 20-year follow-up study [Abstract 511]
34. Effects of the angiotersin converting enzyme inhibitor, captopril, in essential hypertension
35. Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 and MK521
36. Heart rate control in hypertensive patients treated by captopril
37. Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man
38. Reflex-hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal humans
39. Acute and chronic effects of the converting enzyme inhibitor enalapril and lisinopril on reflex control of heart rate in normotensive man
40. Immediate and short-term cardiovascular effects of a new converting enzyme inhibitor (lisinopril) in essential hypertension
41. Clinical use of an orally active converting enzyme inhibitor: captopril
42. Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation
43. Renal response to angiotensin-converting enzyme inhibition
44. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics
45. Sodium intake and renal responses to captopril in normal humans and essential hypertension
46. Effects of captopril on renal function in hypertensive patients
47. The effect of captopril on renal hemodynamics in hypertensive patients
48. Effects of subpressor doses of angiotensin II on renal hemodynamics in relation to blood pressure
49. Effects of enalapril on blood pressure and renal hemodynamics in essential hypertension
50. Renal function and hemodynamics during treatment with enalapril in primary hypertension
51. Control of glomerular filtration rate by reninangiotensin system
52. Intrarenal renin and autoregulation of renal plasma flow and glomerular filtration rate
53. Left ventricular wall stress and systolic function in untreated primary hypertension
54. Restoration of cardiac function and structure by converting enzyme inhibition: possibilities and limitations of long-term treatment in hypertension and heart failure
55. The clinical pharmacokinetics of quinapril
56. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors
57. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe 498 and MK 421, in spontaneously hypertensive rats